China National Healthcare Security Administration: with average decline of 56% in prices, reduced-price drugs will be available in October
On June 23, the fifth batch of national medicine centralized procurement has produced selection results. The scale, amount, and number of participating companies in this centralized procurement are the highest in history. On June 22, National Medical Products Administration approved 17 companies’ application for drug consistency evaluation, involving 9 products for centralized procurement. These companies entered the competition at the last minute and brought new changes to the competitive landscape.

According to statistics, 61 of the 62 drugs won bidding in the procurement, and propranolol oral common-release dosage failed. In this round of purchases, the prices of 24 varieties dropped by more than 90%. Among them, Hengrui’s docetaxel injection, Qilu’s rivaroxaban oral common-release dosage, and Zhaohui Pharmaceutical’s bicalutamide oral common-release dosage all dropped by more than 97%. The average drop in medicine prices was 56%, which was significantly higher than the 52% and 53% drop of previous batches. According to data from National Healthcare Security Administration, five batches of nationally organized drug procurement included a total of 218 drugs, involving an amount of 220 billion yuan, and accounting for 30% of the total chemical drug purchases of public medical institutions. After the selection results are announced and released by the end of June, patients across the country will be able to use the drugs with reduced prices in October 2021.

(source: China Business Journal translation: InsurView)
https://www.reddit.com/r/StockMarket/comments/o7k31l/china_national_healthcare_security_administration/